Switching Treatment from Mepolizumab to Benralizumab for Elderly Patients with Severe Eosinophilic Asthma: A Retrospective Observational Study.

Intern Med · 2022 · PMC9259321 · PMID 35650114

Europe PMC DOI

hedged sentence

0.0770

closest p · 1.5× alpha

0.0770

boldest claim

The sentences

showed a trendp=0.077so close (0.05 < p ≤ 0.1)

The mepolizumab group showed a trend toward decreasing blood eosinophil levels from 337.7±101.3 cells/μL at the pre-treatment baseline to 94.2±63.8 cells/μL 1 year later (p=0.077; Fig. 2B ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.